As of 8:01:03 AM GMT+1. Market Open.
Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Background: Treatment of locally advanced SCCHN usually includes primary/post-op concomitant CRT ...
At close: 9:50:08 pm GMT+1 Loading Chart for HN5.F ...
As of 09:26 CEST. Market open. Loading Chart for HN5.F ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results